XML 39 R19.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Commitments and Contingencies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2014
Commitments and Contingencies [Abstract] |
Summary of milestone payment |
Milestones |  | Payments |
(1) when Company initiates a Phase I Clinical Trial of a licensed product |  | $ | 750,000 |
(2) when Company initiates a Phase II Clinical Trial of a licensed product |  |  | 750,000 |
(3) when Company initiates a Phase III Clinical Trial of a licensed product |  |  | 1,500,000 |
(4) Biological License Application filing with U.S. FDA |  |  | 1,750,000 |
(5) First commercial sale |  |  | 1,500,000 |
(6) after the first $10,000,000 in net sales |  |  | 1,500,000 |

X
- Definition Milestone payments milestone method. + References No definition available. + Details
Name: | atnm_MilestonePaymentsMilestoneMethodTableTextBlock
Namespace Prefix: | atnm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration